ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • Search
  • My Favorites
    • View and print all favorites
    • Clear all favorites

Abstract Number: 765

Predictors of End-Stage Renal Disease in Lupus Nephritis

Mery Deeb1, Konstantinos Tselios2, Dafna D Gladman2, Jiandong Su2 and Murray Urowitz3, 1Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toront, ON, Canada, 2University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 3Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada

Meeting: ACR/ARHP Annual Meeting 2018

Keywords: Nephritis, renal disease and systemic lupus erythematosus (SLE)

  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print
Session Information

Date: Sunday, October 21, 2018

Title: Systemic Lupus Erythematosus – Clinical Poster I: Clinical Manifestations and Comorbidity

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

End-stage renal disease (ESRD) is the most important complication of lupus nephritis (LN) and greatly affects mortality. Its incidence has been estimated at 11% at 5 years and 17% at 10 years after LN diagnosis. The identification of certain predictive factors is of importance for risk stratification and proper management. The aim of the present study was to define the factors associated with ESRD development in a defined cohort of LN patients.

Methods:

Patients with LN (class II-V according to the International Society of Nephrology/Renal Pathology Society classification) were recruited from our long-term longitudinal cohort. Individuals with ESRD (estimated glomerular filtration rate, eGFR≤15 ml/min/1.73m2) at the first two clinic visits after enrolment were excluded. Patients were followed until the occurrence of ESRD (defined as two consecutive visits with an eGFR≤15 ml/min/1.73m2 or initiation of dialysis) or last visit. They were divided in two groups (ESRD or not) and compared as per the demographic, histopathological, clinical and therapeutic variables. Statistical analysis was performed with SAS 9.0; p<0.05 was considered significant. Time-dependent Cox regression analysis was performed for the identification of predictors.

Results:

LN was diagnosed in 560 patients, 43 of whom developed ESRD (7.7%) after 7.5±6.4 years of follow up. There were no differences in demographic variables at baseline. Concerning the histopathologic class, diffuse proliferative LN (class IV) was more frequent in the ESRD patients (51.2% vs. 28.4%, p=0.033). Baseline serum creatinine was higher in the ESRD patients (152±94 vs. 85±41mmol/L, p<0.001); consequently eGFR was lower (61±37 vs. 93±37ml/min/1.73m2 respectively, p<0.001). Hypertension was more frequent in the ESRD patients (58.1 vs. 38.3%, p=0.015). Concerning laboratory values, initial proteinuria was more severe in the ESRD patients (3.2±2.5 vs. 1.9±2.8g/day, p=0.027) whereas hemoglobin was lower (113±18 vs. 120±20g/L, p=0.02). There were no differences in therapeutic variables (dose of glucocorticosteroids, type and dose of immunosuppressives and antimalarials). Patients with ESRD were using angiotensin converting enzyme inhibitors or angiotensin receptor blockers more frequently (34.9 vs. 21.3%, p=0.04). Multivariable Cox regression analysis revealed that hypertension (HR=10.1, 95%CI=4.34-23.8, p<0.001), baseline serum creatinine (HR=1.009, 85%CI=1.008-1.01, p<0.001) and initial prednisone dose (HR=1.016, 95%CI=1.001-1.031, p=0.03) were associated with a higher probability for ESRD development. On the contrary, normal hemoglobin at baseline was protective (HR=0.97, 95%CI=0.95-0.99, p<0.001).

Conclusion:

Initial serum creatinine and hypertension were the most important predictors for the development of ESRD in patients with LN. These findings reinforce the importance of regular monitoring of serum creatinine even in asymptomatic patients as well as the need for strict control of hypertension in LN.


Disclosure: M. Deeb, None; K. Tselios, None; D. D. Gladman, Abbvie, Amgen, BMS, Celgene, Eli Lilly and Company, Janssen, Novartis, Pfizer, UCB, 5,Abbvie, Amgen, Celgene, Janssen, Novartis, Pfizer and UCB, 2; J. Su, None; M. Urowitz, None.

To cite this abstract in AMA style:

Deeb M, Tselios K, Gladman DD, Su J, Urowitz M. Predictors of End-Stage Renal Disease in Lupus Nephritis [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/predictors-of-end-stage-renal-disease-in-lupus-nephritis/. Accessed .
  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print

« Back to ACR/ARHP Annual Meeting 2018

ACR Meeting Abstracts - https://acrabstracts.org/abstract/predictors-of-end-stage-renal-disease-in-lupus-nephritis/

Advanced Search

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology